Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
12:00pm, Saturday, 25'th May 2024
As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resu
The Bottom Fishing Club: Alkermes Has Great Value And Safety
08:27am, Friday, 17'th May 2024
Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol dep
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
07:00am, Tuesday, 14'th May 2024
̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder �
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
12:41pm, Thursday, 02'nd May 2024
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
07:00am, Thursday, 02'nd May 2024
DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In conne
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 01'st May 2024
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
09:31am, Wednesday, 01'st May 2024
Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago.
Alkermes plc Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 01'st May 2024
— First Quarter Revenues of $350.4 Million — — GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 —
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
07:00am, Wednesday, 24'th Apr 2024
DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compa
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
03:16pm, Monday, 22'nd Apr 2024
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
Alkermes to Report First Quarter Financial Results on May 1, 2024
04:00pm, Wednesday, 17'th Apr 2024
DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
11:06am, Wednesday, 17'th Apr 2024
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
11:16am, Thursday, 11'th Apr 2024
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 10'th Apr 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
04:29pm, Tuesday, 09'th Apr 2024
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 stu
